

27 06-27-03

1637

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0034  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED

JUL 02 2003

TECH CENTER 1600/2900

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	09/824,984	
	<b>Filing Date</b>	02 April 2001	
	<b>First Named Inventor</b>	Sharat Singh	
	<b>Group Art Unit</b>	1637	
	<b>Examiner Name</b>	J. Tung	
<b>Total Number of Pages in This Submission</b>		<b>Attorney Docket Number</b>	033.10US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Response  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  1. Form PTO-1449 w/copies of 5 References 2. Return Receipt Postcard
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Stephen C. Macevitz, Reg. No. 30,285
Signature	
Date	26 June 2003

CERTIFICATION OF MAILING BY "EXPRESS MAIL"	
Express Mail Label No.	EV 313 980 548 US
Date of Deposit:	26 June 2003
 Virginia Griffith	I hereby certify that this paper or fee and accompanying documents referred to below are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATION OF MAILING BY "EXPRESS MAIL"

Express Mail Label No. EV 313 980 548 US  
Date of Deposit: 26 June 2003

*Virginia Griffith*  
Virginia Griffith

I hereby certify that this paper or fee and accompanying documents referred to below are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Case No. 033.10US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,984

Filed: 02 April 2001

For: Methods Employing Generalized  
Target-Binding e-tag Probes

Examiner: J. Tung (Prior)

Art Unit: 1637

SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on the accompanying PTO-1449 form(s) may be material to the examination of the above-identified application and are, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application. Copies of the cited references are enclosed or have been previously submitted in prior application(s) to the above application.

This Information Disclosure Statement under 37 CFR 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

### **SUBMISSION INFORMATION**

This Information Disclosure Statement is being submitted within three (3) months of filing or before mailing of a first Office Action, whichever occurs last. (37 CFR 1.97(b))


### **PAYMENT OF FEES (IF ANY DUE)**

**FEE AUTHORIZATION.** The Commissioner is hereby authorized to withdraw from Deposit Account

**50-2266**

any submission fees or petition fees required for this Information Disclosure Statement.

Respectfully submitted,

  
Stephen C. Macevicz  
Registration No. 30,285

Enclosures: 1449 form(s)  
References



RECEIVED

JUL 02 2003

TECH CENTER 1600/2900

Form PTO-1449 (adapted)  <b>REFERENCES CITED BY APPLICANT</b>	Docket No. <b>Aclara ref. 033.10US</b>	Serial No. <b>09/824,984</b>
	Applicant <b>Singh et al</b>	Examiner <b>J. Tung</b>
	Filing Date <b>02 April 2001</b>	Group <b>1637</b>

US PATENT DOCUMENTS

Examiner's Initials		Document Number	First Inventor	Title	Issue/Publication date (mm/dd/yyyy)
	<b>P1</b>	US 5,843,680	Manian	Differential Separation Assay Methods and Test Kits	12/01/1998
	<b>P2</b>	US 5,571,680	Chen	Homogeneous Immunoassays and Enzyme Based Assays of Analytes Using Capillary Electrophoresis	11/05/1996
	<b>P3</b>	US 5,137,609	Manian	Differential Separation Assay	08/11/1992

OTHER REFERENCES

Examiner's Initials		Citation
	<b>D1</b>	Caslavska, J. et al., "Analysis of Urinary Drugs of Abuse by a Multianalyte Capillary Electrophoretic Immunosassay," <i>J Chromatogr A</i> . 1999 Apr 9;838(1-2):197-211.
	<b>D2</b>	Chen, FT. et al., "Feasibility Studies for Simultaneous Immunochemical Multianalysis Drug Assay by Capillary Electrophoresis with Laser-Induced Fluorescence." <i>Clin Chem</i> . 1994 Sept;40(9):1819-22.

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	